25 May 2013
Keywords: BioDiem, NasoVac, Serum Institute of India, Merck & Co, Nobilon, India
Article | 12 July 2010
Australian firm BioDiem’s lead product, the live attenuated influenza vaccine (LAIV) has been granted regulatory approval for marketing in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
12 July 2010
24 May 2013
© 2013 thepharmaletter.com